Literature DB >> 12188886

Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.

S Ghosh1, X P Liu, Y Zheng, F M Uckun.   

Abstract

Increasing knowledge of the structure and function of the Epidermal Growth Factor Receptor (EGFR) subfamily of tyrosine kinases, and of their role in the initiation and progression of various cancers has led to the search for inhibitors of signaling molecules that may prove to be important in cancer therapy. The complex nature of EGFR biology allows for potential opportunities for EGFR inhibitors in a number of areas of cancer therapy, including proliferative, angiogenic, invasive, and metastatic aspects. Different approaches have been used to target either the extracellular ligand-binding domain of the EGFR or the intracellular tyrosine kinase region that results in interference with its signaling pathways that modulate cancer-promoting responses. Examples of these include a number of monoclonal antibodies, immunotoxins and ligand-binding cytotoxic agents that target the extracellular ligand binding region of EGFR, and small molecule inhibitors that target the intracellular kinase domain and act by interfering with ATP binding to the receptor. During the past 3 years, significant progress has been made towards the identification of new structural classes of small molecule inhibitors that show high potency and specificity towards EGFR. The search for new small molecules that inhibit kinases has included traditional approaches like the testing of natural products, random screening of chemical libraries, the use of classical structure-activity-relationship studies, and the incorporation of structure-based drug design and combinatorial chemistry techniques. There has been a significant improvement in the development of selective EGFR inhibitors with the use of a structure-based design approach employing a homology model of the EGFR kinase domain. Molecular modeling procedures have been used to generate novel molecules that are complementary in shape and electrostatics to the EGFR kinase domain topography. This review focuses on some examples of the successful use of this method.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12188886     DOI: 10.2174/1568009013334188

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  8 in total

1.  [11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma.

Authors:  Ming-Rong Zhang; Katsushi Kumata; Akiko Hatori; Nobuhiko Takai; Jun Toyohara; Tomoteru Yamasaki; Kazuhiko Yanamoto; Joji Yui; Kazunori Kawamura; Sachiko Koike; Koichi Ando; Kazutoshi Suzuki
Journal:  Mol Imaging Biol       Date:  2009-09-26       Impact factor: 3.488

2.  3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.

Authors:  Haregewein Assefa; Shantaram Kamath; John K Buolamwini
Journal:  J Comput Aided Mol Des       Date:  2003-08       Impact factor: 3.686

3.  Molecular drug targets and structure based drug design: A holistic approach.

Authors:  Shailza Singh; Balwant Kumar Malik; Durlabh Kumar Sharma
Journal:  Bioinformation       Date:  2006-12-23

4.  Receptor-based virtual screening of EGFR kinase inhibitors from the NCI diversity database.

Authors:  Kiattawee Choowongkomon; Orathai Sawatdichaikul; Napat Songtawee; Jumras Limtrakul
Journal:  Molecules       Date:  2010-06-04       Impact factor: 4.411

Review 5.  Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism.

Authors:  Mohammed A S Abourehab; Alaa M Alqahtani; Bahaa G M Youssif; Ahmed M Gouda
Journal:  Molecules       Date:  2021-11-04       Impact factor: 4.411

6.  Optimizing structural modeling for a specific protein scaffold: knottins or inhibitor cystine knots.

Authors:  Jérôme Gracy; Laurent Chiche
Journal:  BMC Bioinformatics       Date:  2010-10-28       Impact factor: 3.169

Review 7.  The prolyl isomerase Pin1 in breast development and cancer.

Authors:  Gerburg Wulf; Akihide Ryo; Yih-Cherng Liou; Kun Ping Lu
Journal:  Breast Cancer Res       Date:  2003-01-28       Impact factor: 6.466

Review 8.  Utility of homology models in the drug discovery process.

Authors:  Alexander Hillisch; Luis Felipe Pineda; Rolf Hilgenfeld
Journal:  Drug Discov Today       Date:  2004-08-01       Impact factor: 7.851

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.